JP2003515323A5 - - Google Patents

Download PDF

Info

Publication number
JP2003515323A5
JP2003515323A5 JP2001538975A JP2001538975A JP2003515323A5 JP 2003515323 A5 JP2003515323 A5 JP 2003515323A5 JP 2001538975 A JP2001538975 A JP 2001538975A JP 2001538975 A JP2001538975 A JP 2001538975A JP 2003515323 A5 JP2003515323 A5 JP 2003515323A5
Authority
JP
Japan
Prior art keywords
canine
polypeptide
seq
fragment
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001538975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515323A (ja
Filing date
Publication date
Priority claimed from PCT/GB1999/003859 external-priority patent/WO2000029428A2/en
Priority claimed from GB0003527A external-priority patent/GB0003527D0/en
Priority claimed from GB0005071A external-priority patent/GB0005071D0/en
Application filed filed Critical
Priority claimed from PCT/GB2000/004317 external-priority patent/WO2001036486A2/en
Publication of JP2003515323A publication Critical patent/JP2003515323A/ja
Publication of JP2003515323A5 publication Critical patent/JP2003515323A5/ja
Pending legal-status Critical Current

Links

JP2001538975A 1999-11-18 2000-11-13 抗 体 Pending JP2003515323A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB99/03859 1999-11-18
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy
GB0003527.9 2000-02-15
GB0003527A GB0003527D0 (en) 2000-02-15 2000-02-15 Antibodies
GB0005071A GB0005071D0 (en) 2000-03-02 2000-03-02 Antibodies
GB0005071.6 2000-03-02
PCT/GB2000/004317 WO2001036486A2 (en) 1999-11-18 2000-11-13 Scfv antibodies against disease associated molecules

Publications (2)

Publication Number Publication Date
JP2003515323A JP2003515323A (ja) 2003-05-07
JP2003515323A5 true JP2003515323A5 (enExample) 2007-12-20

Family

ID=27255534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001538975A Pending JP2003515323A (ja) 1999-11-18 2000-11-13 抗 体

Country Status (7)

Country Link
US (4) US7074909B2 (enExample)
EP (1) EP1242456B1 (enExample)
JP (1) JP2003515323A (enExample)
CN (1) CN1423660A (enExample)
AU (1) AU1290001A (enExample)
CA (1) CA2391925A1 (enExample)
WO (1) WO2001036486A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
DE60040555D1 (de) * 1999-11-18 2008-11-27 Oxford Biomedica Ltd Küle
CA2391925A1 (en) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Antibodies
US7402666B2 (en) 2000-11-13 2008-07-22 Oxford Biomedica (Uk) Ltd. Nucleotide encoding canine 5T4 antigen
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
EP1578371A4 (en) * 2002-08-19 2009-05-20 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US7714119B2 (en) * 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
CN101035564A (zh) * 2004-09-10 2007-09-12 惠氏公司 人源化的抗5t4抗体和抗5t4抗体/加利车霉素缀合物
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CA2611726C (en) * 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
EP2313784B1 (en) * 2008-07-15 2015-02-18 Oxford BioMedica (UK) Limited Immunotherapeutic method
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
EP2758438A1 (en) * 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispecific binding molecules for 5t4 and cd3
JP6254951B2 (ja) 2012-01-24 2017-12-27 ファイザー・インク 哺乳類の対象における５ｔ４陽性循環腫瘍細胞を検出するための方法および５ｔ４陽性がんの診断の方法
JP2016531088A (ja) 2013-06-17 2016-10-06 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー ５ｔ４標的化免疫融合分子および方法
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
KR102572149B1 (ko) 2013-10-11 2023-08-30 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
CA2926586C (en) 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2015133484A1 (ja) * 2014-03-04 2015-09-11 国立大学法人徳島大学 腎臓疾患に関するマーカー及びその利用
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
CN106749656B (zh) * 2016-11-11 2018-04-13 郑州师范学院 一种抗小鼠RCN3蛋白单克隆ScFv抗体及其淘选方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
WO2019089472A1 (en) 2017-11-01 2019-05-09 Nantbio, Inc. Il8 blocking emt pathway and overcoming cancer stem cells
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021506883A (ja) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピン抗体結合体
CN111971298B (zh) 2018-03-12 2025-06-20 健玛保 抗体
KR20210084546A (ko) 2018-10-29 2021-07-07 메르사나 테라퓨틱스, 인코포레이티드 펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
AR132178A1 (es) 2023-03-22 2025-06-04 Salubris Biotherapeutics Inc Dominios de unión al antígeno anti-5t4, conjugados anticuerpo-fármaco, y métodos de uso de los mismos

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481051A (en) * 1969-02-06 1969-12-02 Paramount Packaging Corp Heating apparatus
US4009778A (en) * 1975-11-04 1977-03-01 The Kartridg Pak Co. Dual compartment package and method for making same
US4267768A (en) * 1976-09-20 1981-05-19 David M. Cieslak Process for fabricating a reclosable bag
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5060146A (en) 1988-04-08 1991-10-22 International Business Machines Corporation Multilingual indexing system for alphabetical lysorting by comparing character weights and ascii codes
WO1990014355A1 (en) 1989-05-17 1990-11-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
EP0621338A3 (en) * 1993-04-21 1997-10-29 Ajinomoto Kk The interleukin-2 response blocking immunosuppressor.
CA2162689C (en) * 1993-05-12 2000-07-18 Xoma Corporation Immunotoxins comprising gelonin and an antibody
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
AU5320296A (en) 1995-03-24 1996-10-16 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US5637462A (en) * 1995-04-19 1997-06-10 Incyte Pharmaceuticals, Inc. Cathepsin C homolog
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
CN1194009A (zh) * 1995-06-06 1998-09-23 人体基因组科学有限公司 结肠特异性基因及蛋白质
DE19531346A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
WO1997017090A1 (en) 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
JP4175678B2 (ja) * 1996-06-07 2008-11-05 武田薬品工業株式会社 新規ペプチド、その製造法および用途
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
JPH1156368A (ja) * 1997-08-27 1999-03-02 Nippon Seibutsu Kagaku Kenkyusho 猫トロンボポエチンの活性を有する因子
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強
CA2351622A1 (en) * 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited Polypeptide
CA2391925A1 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Antibodies
DE60040555D1 (de) * 1999-11-18 2008-11-27 Oxford Biomedica Ltd Küle

Similar Documents

Publication Publication Date Title
JP2003515323A5 (enExample)
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
IL163066A (en) Ligands for the zcytor17 receptor
JP2006516189A5 (enExample)
JP2006516098A5 (enExample)
JP2002524024A5 (enExample)
JP2002519061A5 (enExample)
JP2002537791A5 (enExample)
WO2004035618A3 (en) Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2002101052A3 (en) Salutaridinol 7-o-acetyltransferase and derivatives thereof
JP2002517193A5 (enExample)
JP2002540769A5 (enExample)
WO2003035878A3 (de) Lipase-varianten
WO2001053347A3 (fr) Gene nphs2 implique dans le syndrome nephrotique cortico-resistant, proteine codee par ce gene et utilisations diagnostiques et therapeutiques
JP2006515984A5 (enExample)
WO2003022039A1 (fr) Procede permettant de conferer une resistance a un virus au moyen d'une proteine vegetale se liant a une proteine de transport de virus vegetal
JPH10210974A5 (enExample)
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
EE200100234A (et) PRV-1-geen ja selle kasutamine
JP2004500829A5 (enExample)
SE0001988D0 (sv) Novel polypeptides and use thereof
WO2007073845A8 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
EP1225183A3 (en) Human G-protein coupled receptor